Introduction
Cells are always required to integrate external stress signals and thus decide cell fates to die or survive on an ongoing basis. These fate decisions are made by a wide range of signaling pathways that are controlled by kinases. Developmental programs and environmental agents trigger distinct and evolutionarily conserved kinases (Caffrey et al., 1999; Widmann et al., 1999) that relay signals mediating proliferation, survival, death, or cell cycle arrest. The mitogen-activated protein kinases (MAPKs) are the family of kinases that transduce signals from the cell membrane to the nucleus in response to a wide range of stimuli, including stress Waskiewicz and Cooper, 1995; Tibbles and Woodgett, 1999; Davis, 2000; Chang and Karin, 2001; Johnson and Lapadat, 2002; Werlen et al., 2003) . MAPKs are serine/threonine kinases that, upon stimulation, phosphorylate their specific substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity. Thus, the MAPK signaling pathways modulate gene expression, mitosis, proliferation, motility, metabolism, and programmed death 'apoptosis' Waskiewicz and Cooper, 1995; Tibbles and Woodgett, 1999; Davis, 2000; Chang and Karin, 2001; Johnson and Lapadat, 2002; Werlen et al., 2003) .
Conventional MAPKs consist of three family members: the extracellular signal-regulated kinase (ERK); the c-Jun NH2-terminal kinase (JNK); and the p38-MAPK, and each family member has its own subfamilies: ERKs (ERK1 and ERK2), JNKs (JNK1, JNK2, and JNK3), and p38-MAPKs (p38-MAPKa, p38-MAPKb, p38-MAPKd, and p38-MAPKd) Tibbles and Woodgett, 1999; Widmann et al., 1999; Davis, 2000; Chang and Karin, 2001; Johnson and Lapadat, 2002) (Figure 1 ). An additional MAPK, termed ERK5, has been cloned (Zhou et al., 1995) and ERK5 is a member of a larger MAPK family that also includes ERK7 and ERK8 (Abe et al., 1999 (Abe et al., , 2002 . However, the functions and activation pathways for ERK7 and ERK8 are not fully characterized.
ERK1 and ERK2 are well-characterized MAPKs activated in response to growth stimuli. Both JNKs and p38-MAPK are simultaneously activated in response to a variety of cellular and environmental stresses such as changes in osmolarity or metabolism, DNA damage, heat shock, ischemia, inflammatory cytokines, shear stress, UV irradiation ceramide, or oxidative stress Tibbles and Woodgett, 1999; Widmann et al., 1999; Davis, 2000; Chang and Karin, 2001; Johnson and Lapadat, 2002; Dent et al., 2003) . Interestingly, although there are two stress kinases in mammalian cells, only one stress kinase called Hog1 exists in fission yeast. It is likely that two independent stress kinases, p38-MAPK and JNKs, have evolved to relay an increasing complexity of developmental and environmental cues (Caffrey et al., 1999; Widmann et al., 1999) . Increasing genetic data supports evolution of distinct roles of the two pathways in cellular function.
While p38-MAPKs and JNKs are called stress kinases, many of the stimuli that induce p38-MAPK and JNK stress kinases, such as heat shock, TNF-a, UV irradiation, and cytochalasin D, also activate other MAPK cascades (Dhanwada et al., 1995; Price et al., 1996; Irigoyen et al., 1997) . Thus, the question is how cells integrate different stressors and how they make cell fate decisions for death or survival? Our review will mainly discuss mouse genetic models and summarize recent progress in apoptosis analysis using such models (Table 1) .
JNK pathways
JNKs (also known as stress-activated protein kinases; SAPKs) are ubiquitously expressed, and the JNK stress pathways participate in many different intracellular signaling pathways that control a spectrum of cellular processes, including cell growth, differentiation, transformation, or apoptosis Waskiewicz and Cooper, 1995; Tibbles and Woodgett, 1999; Davis, 2000; Chang and Karin, 2001; Johnson and Lapadat, 2002; Werlen et al., 2003) . JNK has been reported to activate transcription factors in addition to c-Jun, such as ATF2, Elk-1, p53, and c-Myc Karin, 1995; Davis, 2000) as well as nontranscription factors such as Bcl-2 and Bcl-xL (Maundrell et al., 1997; Yamamoto et al., 1999) .
JNKs are directly activated by the phosphorylation of tyrosine and threonine residues in a reaction that is catalysed by the dual-specificity kinase MKK4 and MKK7 (also known as SEK1/JNKK1 and SEK2/ JNKK2) (Sanchez et al., 1994; Yan et al., 1994; Derijard et al., 1995; Moriguchi et al., 1995; Holland et al., 1997; Lu et al., 1997; Tournier et al., 1997) , but by no other known MKKs. Although MKK4 and 7 are structurally related to MEK1 and MEK2, MEKs do not activate JNKs and, conversely, MKK4 and 7 do not activate ERKs. This implies that parallel and independent signaling cascades exist for MAPK and JNK activation (Su and Karin, 1996; Woodgett et al., 1996) to allow for a functional dichotomy among kinase cascades. It has also been shown that both MKK4 and MKK7 are required for full activation of JNKs (Fleming et al., 2000; Wada et al., 2001; Kishimoto et al., 2003) . MKK4 and MKK7 transmit signals from upstream activators such as ASK1, HPK1, MLK-3, or Ste11/Byr 2-homologues MKKK1-4, as well as proteins such as TAK-1 and TPL-2 to activate the JNK pathway (Lange-Carter et al., 1993; Minden et al., 1994a, b; Yan et al., 1994; Coso et al., 1995; Olson et al., 1995; Kiefer et al., 1996; Tibbles et al., 1996; Takeda et al., 2003) . Activation of JNK is also regulated by scaffold proteins such as JIP, b-arrestin, and JSAP1 Ito et al., 1999; McDonald et al., 2000) . JNK activation is negatively regulated by protein phosphatases, such as mitogen-activated protein phosphatases (Karin, 1995) .
It has been proposed that JNK activation triggers apoptosis in response to many types of stress, including UV and g-irradiation, protein synthesis inhibitors (anisomycin), hyperosmolarity, toxins, ischemia/reperfusion injury in heart attacks, heat shock, anticancer drugs (cisplatinum, adriamycin, or etoposide), ceramide, T-cell receptor stimulation, peroxide, or inflammatory cytokines such as TNFa (Westwick et al., 1995; Chen et al., 1996; Cuvillier et al., 1996; Johnson et al., 1996; Zanke et al., 1996) . Moreover, nerve growth factor (NGF) deprivation in PC12 pheochromocytoma cells leads to sustained JNK activation and the induction of apoptosis (Xia et al., 1995) . The overexpression of dominant-negative MKK4 in vitro can block the induction of cell death by heat shock, irradiation, anticancer drugs (cisplatinum, adriamycin, and etoposide), peroxide, ceramide, or cytokine deprivation (Cuvillier et al., 1996; Verheij et al., 1996; Zanke et al., 1996) . In addition, overexpression of inactive c-Jun or dominant-negative MEKK1 has been shown to inhibit the induction of cell death by irradiation, ceramide, or heat shock in U937 and BAE cells (Verheij et al., 1996) , and to protect PC12 cells from apoptosis after NGF withdrawal (Xia et al., 1995) . Overexpression of the JNK-activating MAPKKK homologue apoptosis signal-regulating kinase-1 (ASK1) can mediate apoptosis in mink lung epithelial cells (Mv1Lu cells), human 293 embryonal kidney cells, A673 rhabdomyosarcoma cells, KB epidermal carcinoma cells, and Jurkat T (Ichijo et al., 1997) . ASK-1 is a family member of the MAPKKKs Raf1, Ksr1, Tpl2, Tak1, and MEKK1, and ASK-1 mediates MKK4 and JNK activation in response to TNFa. JNK activation has also been linked to induction of the ICE/CED-3-like protease and apoptosis in response to the DNA-damaging anticancer drugs etoposide (VP-16) or camptothecin (CPT) (Seimiya et al., 1997) . In addition to its importance in stressinduced cell death, JNK activation correlates with Fasmediated apoptosis in human T lymphocytes (Latinis and Koretzky, 1996; Wilson et al., 1996) . The above results might suggest that the ASK1/MEKK1/other upstream kinases sequentially activate MKK4/MKK7, JNK, and c-Jun signaling cascade and execute the induction of apoptosis. To elucidate the hypothesis in vivo and in vitro, numerous studies have been carried out using mouse genetic models (Table 1 ). JNKs have been intensively analysed in mouse genetic models. All JNK alleles are deleted. JNK1 deficient CD4
þ splenic cells and thymocyte show resistance to apoptosis upon stimulation of CD3 (Dong et al., 1998; Sabapathy et al., 2001) . Similarly, JNK2 deficient thymocytes are resistant to anti-CD3 Ab-induced apoptosis (Sabapathy et al., 1999) . These results imply that JNK1 and JNK2 have proapoptotic functions in lymphocytes. With respect to mouse development, each of the single deletion does not result in lethality or ) die around embryonic day 11 with defective neural tube morphogenesis and reduced apoptosis in hindbrain regions (Kuan et al., 1999) .
Jnk1
À/À Jnk2 À/À mouse embryonic fibroblasts (MEFs) also indicate the involvement of JNK activation in proapoptotic function. jnk1 À/À jnk2 À/À MEFs exhibit more resistance to stress-induced apoptosis compared to wild-type cells . Furthermore, it has been reported that active JNK causes the release of apoptogenic factors, such as cytochrome c and SMAC/ Diablo from isolated mitochondria in a cell-free system Chauhan et al., 2003) . These results indicate that the activation of JNK directly regulates mitochondria-dependent apoptosis in a proapoptotic direction.
Another JNK member JNK3 is predominantly expressed in the mouse central nervous system and heart. The jnk3 À/À neurons in CA1 layer of the hippocampus show resistance to excitotoxic killing stimuli (Yang et al., 1997) . A similar phenotype was shown in c-JunA63/73 mice, which carries mutations in the phosphorylation sites of c-Jun (Behrens et al., 1999) . However, the accumulated data using genetic models implicate that JNK activation does not always control apoptosis. For example, in the LCMV infection model, more jnk1 À/À CD8 þ CD44 hi cells undergo apoptosis than wild-type cells indicating that JNK1 is involved in survival of activated T cells (Arbour et al., 2002) .
Besides activation of JNK signaling cascades in response to many types of cellular stress, JNK activity is induced in response to growth factors, heterotrimeric G-proteins, phorbol esters, or co-stimulatory activation of T lymphocytes (Derijard et al., 1994; Minden et al., 1994a; Su et al., 1994; Prasad et al., 1995; Raingeaud et al., 1995) . A number of studies have been carried out to figure out the roles of MKK4/7-JNK-c-Jun module in T cell activation and proliferation. For instance, MKK4 (Nishina et al., 1997) and MKK7 (Dong et al., 2000) have been shown to control IL-2 production. Similarly, data from JNK1/2 double knockout (jnk1
) mice implicates JNK signaling in the regulation of IL2 production in T cells Li et al., 1996; Dong et al., 2000; Sabapathy et al., 2001) . With respect to T cell development, JNK1 and JNK2 are involved in the formation of effector T cells (Dong et al., 1998; Yang et al., 1998) . Similarly, T cells lacking both JNK1 and JNK2 show Th2 cytokine production, suggesting the importance of JNKs for T cell differentiation into Th1 lineage (Dong et al., 2000) . JNK1/2 may also be involved in negative selection of T cells (Sabapathy et al., 1999; Sabapathy et al., 2001) . Failure to activate JNKs in T cells might result in clonal anergy and induction of immunological tolerance (Fields et al., 1996; Li et al., 1996; Williams, 1996) .
Both upstream JNK activating kinases MKK4 and MKK7 have been knocked out in mice. In the absence of MKK4, anisomycin, heat shock, and PMA/Ca 2 þ -ionophore treatment of thymocytes do not induce detectable JNK activity, as to be expected. Genetic inactivation of mkk4 results in embryonic lethality with liver defect between embryonic days 10.5 and 12.5 with increased hepatocyte death Nishina et al., 1999) . It has been recently shown that mkk4 deficient embryonic hepatocytes show decreased JNK activation following hepatocytes growth factor stimulation . These results suggest that MKK4-mediated JNK pathway also participates in embryonic hepatoblast proliferation and survival. Similar to mkk4 mutant mice, genetic ablation of the second JNK activating kinase MKK7 results in embryonic lethality with defects in liver formation and defective hepatocyte proliferation (Wada et al., 2004) . These results indicate that MKK4 and MKK7 cannot substitute for one another in vitro and in vivo and that both are important for hepatocyte proliferation and survival during mouse embryogenesis.
Apoptosis does occur in mkk4 À/À ES cells, mkk4
thymocytes, and mkk4 À/À splenic T cells in response to anisomycin, serum depletion, UV-and g-irradiation, sorbitol-mediated changes in osmolarity, heat shock, anticancer drugs (etoposide, adriamycin, cisplatinum), CD3/CD28 ligation, and PMA/Ca 2 þ ionophore with similar kinetics and at similar doses as in mkk4
þ / þ and mkk4 þ /À cells (Nishina et al., 1997) . Similarly, in other models of apoptosis such as TNFa-induced apoptosis, cell death can be observed in the absence of JNK activation Lenczowski et al., 1997; Natoli et al., 1997) . In MKK4/MKK7 double mutant (mkk4
) MEFs, JNK activation is completely abolished, and these cells exhibit resistance to UVinduced apoptosis (Tournier et al., 2001) . This is in agreement with the observation made in Jnk1
MEFs . In contrast, mkk4
À/À mkk7 À/À ES cells show normal apoptotic responses, including DNA fragmentation and caspase 3 activation, even though apaf1 À/À ES cells exhibit profound defects in the mitochondria-dependent apoptosis. In those mkk4 À/À mkk7 À/À ES cells, the JNK activation by various stresses was again completely abolished . Normal apoptotic responses without JNK activation were also observed in fibroblasts derived from mkk4 À/À mkk7 À/À ES cells . These results raise a question as to whether JNKs are indeed required for the induction of cell death in response to apoptosis inducers. This controversy is also reviewed in other papers (Dougherty et al., 2002; Lisovsky et al., 2002; Lin, 2003) .
Similar to MKKs and JNKs, upstream and downstream modules of the MKK4/7-JNK1/2/3 pathways also show complex and multiple contributions to apoptosis. MEKK1 deficient mice show abolished pressure overload-induced JNK activation and enhanced apoptosis in cardiomyocytes, suggesting that MEKK1 is required for JNK activation following cardiac pressure overload and therefore prevents the heart from apoptosis and failure (Sadoshima et al., 2002) . This idea is also supported by a study which shows that activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress (Dougherty et al., 2002) . Unexpectedly, JNK activation was slightly upregulated in mekk2 À/À thymocytes, and neither ERK nor p38-MAPK activation was affected. Mekk2 À/À thymocytes were more susceptible than wild-type to anti-CD3 MAb-induced cell death (Guo et al., 2002) . The authors concluded that MEKK2 may be required for controlling the strength of TCR/ CD3 signaling. TNFa-and H 2 O 2 -induced sustained activations of JNK and p38-MAPK are lost in ask1 À/À embryonic fibroblasts and such ask1 À/À cells are resistant to TNF-and H 2 O 2 -induced apoptosis (Tobiume et al., 2001) . On the other hand, Fas activation yields comparable apoptotic changes, although Fas-induced JNK and p38-MAPK activities are decreased in ask1 À/À thymocytes. These finding indicate that although ASK1 serves as a critical regulator of JNK and p38-MAPK pathways in Fas signaling, at least in certain cell types ASK1 is not required for Fas-induced apoptosis (Tobiume et al., 2001) .
Similar to mkk4 and mkk7 mutant mice, mice lacking the JNK effector c-Jun die at embryonic day 13 with fetal liver's phenotype. These embryos show massive apoptosis in fetal liver seemingly because of defective proliferation of hepatoblasts (Hilberg et al., 1993; Johnson et al., 1993; Watanabe et al., 2002) . c-Jun deficient 3T3 MEFs show increased spontaneous apoptosis under basal culture conditions, whereas those cells are resistant to UV-induced apoptosis (Shaulian et al., 2000) . In liver-specific c-Jun conditional mutant mice, it has been shown that c-Jun prevents hepatocytes from apoptosis by antagonizing p53 activity (Eferl et al., 2003) . In studies where mice carry mutations in the JNK phosphorylation sites of c-Jun (c-JunA63/A73), the neurons in the CA1 layer of the hippocampus are resistant to excitotoxic killing stimuli.
Thus, even after many years of extensive analyses, the exact effects and functions of JNK signaling on apoptosis are still not known and highly controversial. Since the JNK pathway controls a variety of cell fates such as proliferation (Tournier et al., , 2001 , gene expressions via transcription factors Karin, 1995; Davis, 2000) , cell-cycle re-entry (Shaulian et al., 2000) , the multiple roles of JNK signaling molecules as antiapoptotic, proapoptotic, or no apoptotic should in fact be of no surprise. But even for the same molecule in the same cell type there are different data. For instance, immortalized c-Jun deficient MEFs show more spontaneous cell death compared to wildtype cells, suggesting that c-Jun is important for cell survival. On the other hand, c-Jun deficient MEFs are resistant to UV-induced cell death, indicating that c-Jun is a proapoptotic factor (Shaulian et al., 2000) . How can such results be reconciled?
From our recent results, it appears that the various roles of the JNK pathway in apoptosis depend on the cell types and conditions observed. While late passage mkk7 À/À MEFs are resistant to cell death in the same manner as jnk1
, and mkk4
MEFs (Tournier et al., , 2001 , mkk7 À/À MEFs at earlier cell passages (passages 1-4) undergo apoptosis in response to UV exposure at the same kinetics and to the same extent as mkk7
þ /À and wild-type MEFs (Wada et al., 2004) . These data support the idea that JNK is not always involved in apoptosis, but this pathway rather regulates apoptosis in a signal-specific (and perhaps cell type-dependent) manner. In addition, it has been shown that MKK7 controls cell proliferation but not apoptotic responses to a variety of stimuli . Our results in MEFs indicate that the 'history' and passage numbers of cells is a critical determinant for cell death susceptibility in the absence of MKK7 expression (Wada et al., 2004) . In this apoptotic pathway, the function of JNK seems to be exerted through its effects on gene expression but not direct effect on the effectors of apoptosis. These new findings could also solve the controversial data that have been obtained in different cell types and in different laboratories: the cell type, differences in maturation or differentiation, passage numbers, and cell cycle status would determine the outcome of survival versus death. How JNKs set this molecular death clock needs to be investigated. One of these death and survival clocks could be the regulation of cell cycle molecules (unpublished).
p38-MAPKs pathways
The p38-MAPKs were initially termed as mammalian homologues to the yeast protein Hog1 that sense osmolarity change (Han et al., 1994) . In most cases, p38-MAPKs are simultaneously activated with JNKs (Werlen et al., 2003) . At least four isoforms of p38-MAPK have been known: p38-MAPK a, b, g, and d (Kyriakis and Avruch, 2001) (Figure 1 ). p38-MAPKs are phosphorylated and activated by dual kinases MKK3 and MKK6 at threonine and tyrosine regions. p38-MAPKs control the function of transcription factors, kinases, or phosphatases such as ATF-2, MEF2, MAPKAPK, CDC25, or MSK1/2 (Seger and Waskiewicz and Cooper, 1995; Tibbles and Woodgett, 1999; Davis, 2000; Bulavin et al., 2001; Chang and Karin, 2001) . Rho family GTPases take part in the regulation of p38-MAPK pathway as upstream molecules (Holbrook et al., 1996) and activate p38-MAPKs through PAK1-MKK3/6 (Lee et al., 2001 ). Similar to the JNK pathway, MKK3 and MKK6 are also activated by the upstream protein kinases ASK1, MEKKs, and Tak1. Although those previously known upstream molecules are kinases, it has been recently shown that nonprotein kinase TAB1 can activate p38-MAPK (Ge et al., 2002) . p38-MAPK signaling pathways are involved in a variety of cellular responses, and the outcomes of cellular response are varied and complicated. Similar to JNK pathways, the involvement of p38-MAPK in apoptosis is also diverse. It has been shown that p38-MAPK signaling promotes cell death (Sarkar et al., 2002; Porras et al., 2004) , whereas it has also been shown that p38-MAPK cascades enhance survival (Liu et al., 2001; Park et al., 2002) , cell growth (Juretic et al., 2001) , and differentiation (Yosimichi et al., 2001 ). In CD4 þ T cells, p38-MAPK activity is induced by TCR ligation. Anti-CD3 mAb-induced T cell apoptosis is blocked by specific p38-MAPK inhibitor SB203580 (Zhang et al., 2000) . MKK3 and MKK6 may therefore exhibit proapoptotic signals through the activation of p38-MAPKs, which then induce apoptosis. In contrast, it has been reported that suppression of p38-MAPK activity by SB203580 does not inhibit apoptosis induced by antigen receptors (Salmon et al., 1997) . In addition, the lethal factor from the bacterium Bacillus anthracis induces apoptosis of activated macrophages by cleaving the amino-terminal extension of MKK3 and MKK6. Cells that express the cleavage resistant forms of MKK3 and MKK6 are resistant to B. anthracis-induced apoptosis (Park et al., 2002) . These data therefore indicate that the p38-MAPK pathway is required for apoptosis and survival depending on cell types and conditions.
The p38-MAPK pathway has also been extensively studied through mouse genetic models. Inactivation of p38-MAPKa results in embryonic lethality (Adams et al., 2000; Tamura et al., 2000) around embryonic day 11 with defective placental development. Moreover, one of the groups also suggested that p38a-MAPK plays a critical role, linking developmental and stress-induced erythropoiesis through regulation of Epo mRNA stabilization (Tamura et al., 2000) . Although p38-MAPKs were previously thought to be mostly involved in inflammation and stress response, these experiments suggest that p38-MAPKa also participates in development. Both upstream kinases of p38-MAPKs, MKK3 and MKK6, were deleted. mkk3 À/À mice are viable but were defective in interleukin-12 (IL-12) production by macrophages and dendritic cells (Lu et al., 1999) . However, most cytokines in these cells are normally induced following endotoxin exposure, although mkk3 À/À macrophages display reduced endotoxin-induced p38-MAPK activity (Lu et al., 1999) . mkk6 À/À mice are also viable and fertile, with no detectable developmental abnormalities. However, in vivo deletion of double positive thymocytes in mkk6 À/À mice is impaired, in contrast mkk3 À/À mice show no apparent abnormality in thymocyte development or thymocyte deletion. Conversely, CD4 þ T cells from mkk3 À/À , but not from mkk6 À/À mice, are resistant to activation-induced cell death and cytokine-withdrawal-induced apoptosis (Tanaka et al., 2002) . In T cell-specific (lck promoter driven) transgenic mice that carry a constitutively active form of MKK6 (MKK6[Glu]), p38-MAPK is constitutively activated, and fetal thymocyte development is blocked. However, the activation of p38-MAPK pathway does not cause increased cell death of thymocytes in vivo (Diehl et al., 2000) . These data suggest that p38-MAPK pathways are not always involved in nor are they essential for apoptosis. The involvement of the p38-MAPK pathways in T cell apoptosis and different T cell functions might be related to the expression level of MKK3 and MKK6 since MKK3 and MKK6 show differential expression patterns and expression levels during T cell development (Tanaka et al., 2002) .
To explore p38-MAPK binding partners, yeast twohybrid screening was performed, and MEF2C was identified as a p38-MAPK binding protein . It has been shown that MEF2 is phosphorylated by all of four p38-MAPK isoforms and gain facilitated transcriptional activity (Han and Molkentin, 2000) . MEF2 is required for the postnatal growth of the myocardium (Kolodziejczyk et al., 1999; Lu et al., 2000a) . MEF2 is upregulated and phosphorylated by p38-MAPK during cardiac hypertrophy (Kolodziejczyk et al., 1999; Lu et al., 2000a) . The p38-MAPK pathway promotes skeletal muscle differentiation (Zetser et al., 1999; Lu et al., 2000b) and expression of proinflammatory cytokines during a host response to bacterial pathogens via MEF2c phosphorylation. The p38-MAPKa/MEF2 pathway can rescue neurons from cell death during neuronal differentiation, and a constitutively active form of MEF2C (MEF2VP16) attenuates apoptosis in differentiating cells Mao and Wiedmann, 1999; Okamoto et al., 2000) . T-lymphocyte apoptosis is controlled by MEF2-NFAT interactions via the expression of Nur77 gene (Blaeser et al., 2000; Youn et al., 2000) , which has been known as a mediator of apoptosis in thymocyte (Liu et al., 1994; Woronicz et al., 1994) . Mice lacking MEF2A show heart dysfunctions and die within the first week of age, suggesting that MEF2A is important for cardiomyocyte survival (Naya et al., 2002) . MEF2C deficient mice die at embryonic day 9.5 and display a disorganized vascular system ; however, little is described regarding the apoptosis in MEF2C mutant mice. Other p38-MAPK downstream molecules, such as MAPKAPK2, are also deleted: cells from MAPKAPK2 deficient mouse brain are more resistant to ischemia-induced apoptosis probably due to the reduced production of IL-1 . On the other hand, no obvious phenotype was found in MAPKAPK5 knockout mice (Shi et al., 2003) .
In mammalian cultured cells, the p38-MAPK pathway is activated during the spindle assembly checkpoint and mitotic arrest (Takenaka et al., 1998) . In line with this finding, it has been shown that activation of p38a-MAPK by exposure to UV leads to G2/M cell cycle arrest by suppressing CDC2 via the phosphatase CDC25 (Bulavin et al., 2001) . CDC2 can induce the phosphorylation of the BH3-only protein BAD and thus trigger neuronal apoptosis (Konishi et al., 2002) . Since it has been proposed that the mechanisms that regulate the cell cycle also play a role in apoptosis (King and Cidlowski, 1995) , it would be interesting to examine whether the effects of the p38-MAPK pathways on the regulation of apoptosis are linked to the cell cycle. In conclusion, similar to the JNK pathways, p38-MAPK signaling plays multiple roles in cells such as differentiation, proliferation, cytokine secretion, as well as cell death.
ERKs
Cumulative efforts from many laboratories over the past decades have elucidated the ERK signaling cascade (Sturgill et al., 1988; Boulton et al., 1990; Ahn et al., 1991; Cowley et al., 1994; Seger and Krebs, 1995; Chang and Karin, 2001; Dent et al., 2003) . In the budding yeast, Saccharomyces cerevisiae, four separate but structurally related MAPK activation pathways are known (Caffrey et al., 1999) . The best understood of these regulates is mating. Pheromone binding to its receptor informs cells of the proximity of a mating partner and induces differentiation to a mating competent state. The Ste11-Ste7 signaling pathway mediates this signal (Gartner et al., 1992) . The mammalian counterpart of the Ste11-Ste7 signaling pathway is the MEKs-ERKs cascade.
ERKs are activated by the phosphorylation of a threonine and a tyrosine residue by the dual-specificity MAPK kinases MEK1 and MEK2, which relay Ras and Raf signal transduction to ERK1 and ERK2 (Crews et al., 1992; Alessi et al., 1994) (Figure 1) . Following activation, ERKs translocate to the nucleus and phosphorylate a variety of substrates such as the 90 kDa ribosomal S6 protein kinase called p90RSK, the cytosolic phospholipase A2, or several transcription factors including c-Myc, Elk-1, NF-IL6/C/EBPb/NF-M, Tal-1, Ets-2, and possibly STAT proteins (Davis, 1993; Janknecht et al., 1993; Marais et al., 1993; Kowenz-Leutz et al., 1994; Wadman et al., 1994; Gille et al., 1995; Treisman, 1996) . ERK1 and ERK2 are activated by various growth factors and induce transition from the quiescent state into the cell cycle. ERK signaling pathways are also involved in cell proliferation, differentiation, actin cytoskeleton reorganization, and cell migration. Moreover, ERKs are also involved in the stress response and cell death Waskiewicz and Cooper, 1995; Tibbles and Woodgett, 1999; Davis, 2000; Chang and Karin, 2001; Johnson and Lapadat, 2002; Werlen et al., 2003) .
It has been shown that irradiation stresses lead to phosphorylation of the epidermal growth factor receptor (EGFR, also called HER1) in cancer cell lines (Balaban et al., 1996; Schmidt-Ullrich et al., 1997; Kavanagh et al., 1998) . Recent publications also demonstrate that such EGFR phosphorylation is mediated by radiation-induced free radicals and results in activation of ERKs (Leach et al., 2001) . Similarly, UV irradiation induces the activation of ERK in a number of cell types, and the UV-induced ERK activation also involves the activation of EGF receptors (Coffer et al., 1995; Kitagawa et al., 2002) .
The differential contribution of different MAPK family members to cell death has been examined after withdrawal of NGF from rat PC-12 pheochromocytoma cells (Xia et al., 1995) . NGF withdrawal led to sustained activation of the JNK and p38-MAPK and inhibition of ERKs. The effects of dominant-interfering or constitutively activated forms of various components of the JNK, p38-MAPK, and ERK signaling pathways demonstrated that activation of JNK and p38-MAPK and concurrent inhibition of ERK are critical for induction of apoptosis in these cells. These results suggest that ERK is a survival factor, and JNK and p38-MAP kinases exert opposing effects on apoptosis in this experimental cell line system (Xia et al., 1995) . erk1 À/À mice are viable, fertile, and appear normal. However, erk1 À/À thymocytes show defective proliferation in response to activation with a monoclonal antibody to the T cell receptor in the presence of phorbol myristate acetate, even though activation of p42 MAPK was more sustained in these cells (Pages et al., 1999) . Activation-induced apoptosis of thymocytes is unimpaired in erk1 À/À mice. It is likely that ERK2 can compensate for the loss of ERK1 functions. To date, erk2 mutant mice have not been reported yet. Mice that lack the upstream ERK activator MEK1 die at embryonic day 10.5 exhibiting defective placental vascularization (Giroux et al., 1999) . In the studies where a dominant-negative form of MEK1 is expressed in mouse thymocytes, positive selection of these cells is inhibited but negative selection and TCR-induced proliferation are unaffected (Alberola-Ila et al., 1995) . mek2 mutant mice are viable and fertile and they do not present morphological alteration. Although several components of the ERK/MAP kinase cascade have been implicated in thymocyte development, no such involvement was observed for MEK2, which appears to be nonessential for thymocyte differentiation and T-cellreceptor-induced proliferation and apoptosis (Belanger et al., 2003) . The deletion of the upstream molecule Raf-1 also results in embryonic lethality with a similar phenotype as mek1 knockout mice, including increased apoptosis of embryonic tissues (Huser et al., 2001) . In raf-1 À/À MEFs, apoptosis induced by etoposide and antiFas Abs was increased (Huser et al., 2001) .
Taken together, the MEK1/2-ERK1/2 pathway has multiple functions in a variety of cell types and appears to be important for antiapoptotic signals. While the regulations of apoptosis by the ERK pathway appear to be less complicated than for JNK and p38-MAPKs, there are still unclear aspects. For example, cellmigration assays indicate that mek1 À/À fibroblasts cannot be induced to migrate by fibronectin, although the levels of MEK2 protein and ERK activation are normal. These results indicate a unique role of MEK1 besides activation of ERK (Giroux et al., 1999) . Moreover, in embryonic raf-1 À/À MEFs, apoptosis is increased even though there is no alteration in growth factor-induced ERK1/2 activation (Huser et al., 2001) . It would be interesting to examine whether Raf-1 and MEK1 have other specific substrates involved in cell migration and apoptosis. The molecular frameworks by which ERK, JNK, and p38-MAPK signaling cascades cooperate, concert control of cell fates by other signaling, and networks in different cell types must be the focus of future studies.
ERK5, 7 and 8
ERK 5 is also a member of the MAPK family (Lee et al., 1995; Zhou et al., 1995) . While the molecular sizes of ERKs, JNKs, and p38-MAPKs are between 38 and 54 kDa, ERK5 has a mass of 90 kDa. Therefore, ERK5 is also called 'big' MAP kinase or BMK1. N-terminal half of ERK5 shares sequence homology with other members of the MAP kinase family, whereas ERK5 has a unique large C-terminus. ERK5 is phosphorylated and activated by the MAP kinase kinase MEK5, but not by MEK1 or MEK2. Conversely, MEK5 is specific for ERK5 and does not phosphorylate any other MAPKs (English et al., 1995) . In contrast to ERK1 and ERK2, ERK5 is activated only by neurotrophins (Watson et al., 2001) . ERK5 exhibits higher expression in the mouse brain during early embryonic development. Importantly, well-known MEK1/2 inhibitors PD98059, U0126, and PD184352 also attenuate MEK5 activity (Mody et al., 2001) . ERK5 has been shown to phosphorylate the transcription factors MEF2C and SAP1 (Kato et al., 1997; Kamakura et al., 1999) and transduce signals to the nucleus. Because of the similarity among ERK1/2 and ERK5, the ERK5 cascade has been proposed to enhance cell growth and cell survival rather than apoptosis.
ERK5 is indeed involved in cell survival. In breast carcinoma cells, MEK5 shows a protective effect against chemotherapeutic reagents and death receptor activation (Weldon et al., 2002) . Expression of a dominantnegative ERK5 blocked brain-derived neurotrophic factor protection against trophic withdrawal in primary cortical neurons. These protections appear to be mediated via the ERK5 substrate myocyte enhancer factor 2 (MEF2) (Liu et al., 2003) . In growth-factordeprived PC12 cells, the ERK1, ERK2, and ERK5 pathways are activated, and inhibition of these pathways by PD98059/U0126 results in reduced cell survival (Suzaki et al., 2002) . Expression of dominant-negative ERK5 blocked brain-derived neurotrophic factor protection and induced apoptosis in primary embryonic cortical cultured neurons (Liu et al., 2003) . Thus, the MEK5-ERK5 pathway appears to control cell survival. Deletion of ERK5 gene in mice shows lethality at embryonic day 9.5-10.5 with disorganized cardiovascular systems (Regan et al., 2002; Sohn et al., 2002) . The roles of ERK5 and MEK5 in adult tissues are not known.
Another big MAPK, called ERK7, is activated by autophosphorylation, which is regulated through interactions with its own C-terminal domain (Abe et al., 2001) . In addition, the C-terminal region is also required for the localization of ERK7 into the nucleus to suppress cell growth (Abe et al., 1999) . Owing to the genome and cDNA databases, an additional member of the ERK family, called ERK8 was cloned. ERK8 shares 69% amino-acid sequence identity with ERK7 (Abe et al., 2002) and has extended C-terminal regions. However, in contrast to constitutively active ERK7, ERK8 has minimal basal kinase activity and a unique substrate profile. ERK8 contains two SH3-binding motifs in its C-terminal region and associates with the c-Src SH3 domain. ERK8 is activated following serum stimulation via Src family proteins. ERK8 also has distinct upstream molecules and does not require MEK1, MEK2, or MEK5. Little is known about the biological functions of ERK7 and 8 in apoptosis and/or cell growth.
MAPKs and cancer
Tumors develop when delicate balance among cell cycle, proliferation, differentiation, and apoptosis is disrupted by genetic and/or environmental cues (Hanahan and Weinberg, 2000) . During malignancies, MAPK signaling cascades are deregulated and an intensive research effort incorporating a number of novel therapeutic strategies aimed at restoring proper MAPK function in tumor cells is being applied (Sebolt-Leopold, 2000; English and Cobb, 2002) . For instance, ERK1/2 pathways are hyperactivated in leukemia (Platanias, 2003) , epithelial and many other tumor cells from human patients (Bos, 1989; Robinson et al., 1996; Rowinsky et al., 1999; Sebolt-Leopold, 2000; English and Cobb, 2002; Hilger et al., 2002) . The ERK5 pathway is also upregulated in cancer cells (Robinson et al., 1996; Pearson et al., 2001; Mehta et al., 2003) . These results suggest that ERK1/2 and ERK5 cascades are involved in tumor cell survival and/ or proliferation and thus may be potential targets for cancer therapy.
However, the potential involvement of JNK pathways in both proliferative and apoptotic pathways makes prediction of the involvement of JNK signaling in cancer more complex. As alluded to above JNK pathways exhibit two antagonistic roles (1) oncogenic and (2) proapoptotic.
(1) Oncogenic function of JNK pathways: c-Jun was cloned as a proto-oncogene (Bohmann et al., 1987) . cJun is indeed highly expressed in cancer cells and promotes cell proliferation (Mathas et al., 2002) . JNKs were identified as c-Jun kinases that phosphorylate and activate c-Jun transcriptional activity (Sanchez et al., 1994) . In this scenario, the JNK-c-Jun cascade seems to be an oncogenic pathway promoting cell cycle progression. This idea is also supported by the studies which show that the JNK pathway is required for c-Met oncogene-induced transformation (Rodrigues et al., 1997) . Interestingly, it has been shown that, in addition to kinases such as fyn, itk, tyk2, c-fms, c-kit, cak, and tie-1, the JNK activating kinase MKK4 is highly expressed in gastric carcinoma cells . MKK4 is also highly expressed in prostate carcinoma (Robinson et al., 1996) . In contrast, it has been reported that two human tumor cell lines, derived from pancreatic and lung carcinomas, harbor homozygous deletions that eliminate coding portions of MKK4. In addition, two nonsense and three missense sequence variants of MKK4 were found in cancer cell lines derived from human pancreatic, breast, colon, and testis (Teng et al., 1997; Su et al., 2002) .
These data give rise to the question of whether a mutant MKK4 represents the source of the cancer or simply an indicator of the resultant genomic instability. To our knowledge, there has been no clear demonstration that the JNK pathway attenuates cellular transformation. Instead, it has been shown that the JNK signaling cascade is required for cellular transformation in MEFs (Rodrigues et al., 1997) . Moreover, c-Jun has been shown to abrogate the expression of the tumor suppressor p53 in MEFs . Therefore, the JNK cascade seems to initiate cellular transformation rather than execute apoptosis at least in normal, low passage proliferating cells.
(2) Proapoptotic function of JNK: JNK is required for the apoptosis induced by chemotherapeutic agents (Yu et al., 1996; Chen et al., 1999; Laurent and Jaffrezou, 2001; Stadheim and Kucera, 2002) . In the immortalized and cancer cells, JNK cascades likely change gene expressions and set the cellular susceptibility to apoptotic stimuli. Therefore, mutants found in the MKK4 gene (Teng et al., 1997; Su et al., 2002 ) might promote cancer cell survival. Recently, our group found that the MKK7/JNKc-Jun pathway controls G2/M cell cycle progression in MEFs (Wada et al., 2004) . Since molecules involved in cell cycle also have important roles in apoptosis (King and Cidlowski, 1995) , it might be possible that the JNK pathways promote cell cycle entry and hence increase cell sensitivity to cancer drugs. Thus, stage-and cell type-dependent suppression or activation of JNK might be required for cancer therapy.
Similar to the complexity of the role of JNK in apoptosis, the role of p38-MAPK in cancer is not straightforward. For example, the p38-MAPK signaling pathways promote and suppress proliferation of leukemia cell lines (Platanias, 2003) . Since p38-MAPK also regulates both gene expression Waskiewicz and Cooper, 1995; Tibbles and Woodgett, 1999; Davis, 2000; Chang and Karin, 2001; Johnson and Lapadat, 2002; Werlen et al., 2003) and cycle progression (Bulavin et al., 2001) , viable approaches to cancer therapy through p38-MAPK signaling pathway would likely as complex as that described for modulation of the JNK cascade.
Conclusion
Distinct MAPK pathways control and determine the cell fate in response to a variety of stimuli. MAPK signaling may either protect or enhance sensitivity to apoptosis depending on the cell type, stimuli, and the latency of the activation of MAPKs. The MAPK pathways play important regulatory roles for a variety of downstream molecules such as transcription and translation factors, cell cycle molecules, kinases, or scaffold proteins, and thus exert a variety of cellular outputs, including cell proliferation, cycle arrest, migration, differentiation, senescence, and apoptosis. These multiple downstream targets, cell type-, and cell cycle-specific molecular crosstalks or kinetics and timing of activation may give rise to the complexity of MAPK effects on apoptosis. The balance of these ultimately determines cell fates.
Our recent results in MEFs indicate that the 'history' and passage numbers of cells are a critical determinant for cell death susceptibility in the absence of MKK7 expression (Wada et al., 2004) . In this apoptotic pathway, the function of JNK seems to be exerted through its effects on gene expression but not a direct effect on the effectors of apoptosis. These new findings could also solve the controversial data that have been obtained in different cell types and in different laboratories: the cell type, differences in maturation or differentiation, passage numbers, and cell cycle status may determine the outcome of survival versus death. How JNKs and other MAPKs set this molecular death clock needs to be investigated.
